Videos

Here are the top 5 biosimilar articles for the week of April 15, 2024.

A clinical pharmacist discusses the role of pharmacy benefit managers and payers in accessibility of adalimumab biosimilars.

Experts talk about the impact of the launch of adalimumab biosimilar on their clinical practices and pharmacy.

Here are the top 5 biosimilar articles for the week of April 8, 2024.

Intellectual property attorney Ha Kung Wong, JD, describes the patent dance and how it is designed to streamline information exchange while avoiding unnecessary lawsuits by allowing early assessment of patent infringement and validity.

Specialists in rheumatology, dermatology and gastrointestinal disease discuss clinical trials that have shown safety and efficacy of adalimumab biosimilars in inflammatory diseases.

A clinical pharmacist reviews the various pharmacological aspects of the available adalimumab biosimilars.

Here are the top 5 biosimilar articles for the week of April 1, 2024.

Clinicians and a pharmacist provide an overview of the emerging adalimumab biosimilars in the recent years.

Drs Lio, Botsoglou, and Alexrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval.

Here are the top 5 biosimilar articles for the week of March 25, 2024.

Ha Kung Wong, JD, an intellectual property attorney, discusses lawsuits by drug companies aimed at delaying competition from biosimilars, but the effectiveness of these lawsuits in hindering biosimilar access remains uncertain.

Here are the top 5 biosimilar articles for the week of March 18, 2024.

Here are the top 5 biosimilar articles for the week of March 11, 2024.

Intellectual property attorney, Ha Kung Wong, JD, discusses concerns about "bad patents" hindering biosimilar access, but assures that the FDA and United States Patent and Trademark Office are working to improve the system.

Here are the top 5 biosimilar articles for the week of March 4, 2024.

Here are the top 5 articles for the week of February 26, 2024.

Ha Kung Wong, JD, examines proposed patent law changes that could significantly impact the biosimilars sector, including limitations on asserted patents, elimination of interchangeability requirements, and heightened oversight of pharmacy benefit managers.

Here are the top 5 biosimilar articles for the week of February 19, 2024.

Here are the top 5 biosimilar articles for the week of February 12, 2024.

In an interview with Ha Kung Wong, JD, he addresses the patent legal system biosimilars are required to undergo and how this helps resolve patent disputes early in the development process.

Here are the top 5 biosimilar articles for the week of February 5, 2024.

Here are the top 5 biosimilar articles for the week of January 29, 2024.

Here are the top 5 biosimilar articles for the week of January 22, 2024.

Here are the top 5 biosimilar articles for the week of January 15, 2024.

Here are the top 5 biosimilar articles for the week of January 8, 2024.

Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, reacts to recent FDA approvals for the first natalizumab and tocilizumab biosimilars.

Here are the top 5 biosimilar articles for the week of January 1, 2024.

Here are the top 5 biosimilar articles for 2023.

Brian Biehn and Corey Ford from Cencora suggest improvements to current regulatory frameworks to better promote biosimilars for US patients and ensure market sustainability.